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Objectives: To describe the phenotype associated with the 711+1 G>T mutation
when associated with various other common CFTR mutations compared to the most
common DF508 mutation in a similar setting.
Methods:We have retrospectively reviewed the clinical charts of adult and pediatric
patients with a single 711+1G>T mutation combined with another CFTR mutation
in patients with CF over a 15 year period (1997–2012) in Quebec City, Canada to
compare them to patients with a DF508 mutation but similar other characteristics.
We have evaluated variables for nutritional, respiratory and infectious outcomes as
well as common CF complications.
Results: All measured variables for respiratory (FEV1), nutritional (BMI and
BMI%), infectious (age at ﬁrst Pseudomonas colonization, presence of other
pathogens) status and presence of complications (diabetes, signiﬁcant liver disease,
nasal polyps) as well as initial characteristics at diagnosis (sweat test value, age at
clinical diagnosis, pancreatic status) were similar (p> 0.05) between patients with
a 711+1G>T mutation and a DF508 mutation when other initial factors were taken
into account including the mutation on the second allele.
Conclusion: Patients with a X/711+1G>T genotype are expected to have a similar
clinical course as patients with a X/DF508 genoytype. Genetic counseling for these
patients can therefore be done in a similar way.
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Objectives: Although majority of over 1600 mutations identiﬁed in CFTR gene
are point mutations or small deletions/insertions, large gene rearrangements have
been reported with a relatively high frequency in various ethnic groups. The aim
of our study was to deﬁne the incidence of CFTR gene rearrangements in Serbian
CF patients in which one or no mutation was identiﬁed after the detection of 7 most
common mutations (c.1521_1523delCTT, c.489+1G>T, c.1624G>T, c.1652G>A,
c.1657C>T, c.1585−1G>A, c.3909C>G) or after the sequencing of the whole CFTR
gene.
Methods: Out of 154 patients referred to our Laboratory for molecular anal-
ysis, the clinical diagnosis was not conﬁrmed in 27 patients. Seven CFTR
rearrangements (dele1: c.4_53+69del53+4192_53+4489invinsG; dele2: c.54–
5811_164+2186del273+6780_237+6961inv; dele2_3: c.54–5490_273+10250del;
dele14b_17b: c.2620–674_3367+198del; dele17a_18: c.2988+1173_3468+2111del;
dele22_23: c.3964−78_4242+577del; dele22_24: c.3964–3890_3143delinsTAACT)
were detected by duplex PCR assay. The breakpoints were conﬁrmed by sequencing.
Results: We identiﬁed CFTR gene rearrangements in 3/27 patients. In one patient
dele2 was identiﬁed (genotype c.1521_1523delCTT/dele2), and in two dele2_3 was
identiﬁed (genotypes: c.1521_1523delCTT/dele2_3 and c.1753G>T/dele2_3) thus
conﬁrming clinical CF diagnosis.
Conclusions: These results are in concordance with our previous ﬁndings that the
molecular basis of CF in Serbia is highly heterogeneous. It would be beneﬁcial if
the detection of these rearrangements would be incorporated in routine diagnostic
analysis of CF since their incidence was relatively high and the method was reliable
and inexpensive.
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Cystic Fibrosis (CF) is caused by combination of two mutant allels at the cystic
ﬁbrosis conductance regulator gene (CFTR). There has been a steady increase in the
number of reports of polymutant variants on the same allele (complex alleles). The
aim of this study was to determine if polymutant alleles are present in Venezuelan
patients. For this purpose, 100 patients was studied all of which are included in the
national program of CF and have clinical symptoms of CF. Detection of the mutation
was performed by PCR ampliﬁcation of 27 exons of CFTR gene which contains the
codon that encodes for CFTR protein, and sequenced by automated sequencing at
ABI3130XL. The allelic frequency was 38% vs. 62% WT allele, distributed in 18%
two alleles mutated and 40% only one allele mutated. Patients which were diagnosed
with two mutations, previously reported as complex alleles in the cystic ﬁbrosis
database (http://www.genet.sickkids) were veriﬁed by family testing. We found
only two patients with allele complex, Allele 1: p.P508del/W–p.I1027T/WT in
heterozygous condition and Allele 2: p.G628R–p.S1235R in homozygous condition,
these alleles were conﬁrmed with genetic characterization of both parents for each
patient. It is important to detect the presence of complex alleles in our population, in
order to be taken into consideration when performing genetic studies for molecular
diagnostic purposes, preventing the reports of false positives. The report of the
frequency of these cases and to know their clinic presentation would increase the
knowledge of the phenotypic consequences of CFTR mutations and help to better
understand the relationship between CFTR structure and function.
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Objectives: Cystic Fibrosis (CF) is one of the 23 disorders included in the Norwegian
national neonatal screening program. Testing is performed using a three-tier Immunore-
active trypsinogen (IRT)/DNA/DNA protocol. We present the frequencies of disease
related CFTR mutations identiﬁed in 2nd and 3rd tier and the corresponding IRT values
from the ﬁrst 22 months of screening.
Methods: IRT was measured using GSPTM (Perkin Elmer) and samples >60 ng/mL
were included for 2nd tier. This involved Luminex-based analysis of 71 mutations as
well as Sanger sequencing of a local common mutation. If only one mutation was
found, 3rd tier testing included sequencing of an additional panel of clinically rare
alleles found among Norwegian CF patients.
Results: DNA assessments revealed 23 children with 2 CFTR mutations and 85
with only one CFTR mutation. Only 17 different CFTR variants in our DNA panel
were identiﬁed. Table 1 shows the distribution of the most frequent alleles and the
corresponding range of IRT values.
Table 1. The 6 most frequent CFTR variants and IRT values
Variant n Allele
frequency, %
Min IRT,
ng/mL
Max IRT,
ng/mL
p.R117H 43 32.8 60.2 162.5
p.F508del 39 29.8 60.0 134.4
p.R117C 17 13.0 61.1 155.7
c.3873+2T>C 6 4.6 70.0 124.3
c.262_263delTT 6 4.6 63.7 155.7
c.3528delC 3 2.3 68.6 91.4
Conclusion: The screening program identiﬁed a limited numbers of the CFTR variants
previously reported clinically. Some carriers revealed IRT values signiﬁcantly above
the cut-off level. The most frequent CFTR mutations were p.R117H, p.F508del, and
p.R117C. Taken together, this suggests a review of the IRT/DNA protocol.
